CN108026512B - 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系 - Google Patents

具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系 Download PDF

Info

Publication number
CN108026512B
CN108026512B CN201680049392.8A CN201680049392A CN108026512B CN 108026512 B CN108026512 B CN 108026512B CN 201680049392 A CN201680049392 A CN 201680049392A CN 108026512 B CN108026512 B CN 108026512B
Authority
CN
China
Prior art keywords
cells
cell
trail
cancer
khyg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680049392.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN108026512A (zh
Inventor
迈克尔·埃蒙·彼得·奥德怀尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onkimmune Ltd
Uk Medical Ltd
Original Assignee
Onkimmune Ltd
Uk Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1603655.0A external-priority patent/GB201603655D0/en
Priority claimed from GBGB1610164.4A external-priority patent/GB201610164D0/en
Application filed by Onkimmune Ltd, Uk Medical Ltd filed Critical Onkimmune Ltd
Priority to CN202211000656.4A priority Critical patent/CN116064401A/zh
Priority to CN202210987123.3A priority patent/CN116064400B/zh
Publication of CN108026512A publication Critical patent/CN108026512A/zh
Application granted granted Critical
Publication of CN108026512B publication Critical patent/CN108026512B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201680049392.8A 2015-07-29 2016-07-28 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系 Active CN108026512B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202211000656.4A CN116064401A (zh) 2015-07-29 2016-07-28 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系
CN202210987123.3A CN116064400B (zh) 2015-07-29 2016-07-28 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP15178899.9 2015-07-29
EP15178899 2015-07-29
GB1603655.0 2016-03-02
GBGB1603655.0A GB201603655D0 (en) 2016-03-02 2016-03-02 Modified natural killer cells and natural killer cell lines having increased cytotoxicity
GB201605457 2016-03-31
GB1605457.9 2016-03-31
GBGB1610164.4A GB201610164D0 (en) 2016-06-10 2016-06-10 Modified natural killer cells and natural killer cell lines having increased cytoxicity
GB1610164.4 2016-06-10
PCT/EP2016/068001 WO2017017184A1 (en) 2015-07-29 2016-07-28 Modified natural killer cells and natural killer cell lines having increased cytotoxicity

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202211000656.4A Division CN116064401A (zh) 2015-07-29 2016-07-28 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系
CN202210987123.3A Division CN116064400B (zh) 2015-07-29 2016-07-28 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系

Publications (2)

Publication Number Publication Date
CN108026512A CN108026512A (zh) 2018-05-11
CN108026512B true CN108026512B (zh) 2022-09-16

Family

ID=56683913

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201680049392.8A Active CN108026512B (zh) 2015-07-29 2016-07-28 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系
CN202210987123.3A Active CN116064400B (zh) 2015-07-29 2016-07-28 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系
CN202211000656.4A Pending CN116064401A (zh) 2015-07-29 2016-07-28 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210987123.3A Active CN116064400B (zh) 2015-07-29 2016-07-28 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系
CN202211000656.4A Pending CN116064401A (zh) 2015-07-29 2016-07-28 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系

Country Status (13)

Country Link
US (3) US10034925B2 (enExample)
EP (6) EP3971284B1 (enExample)
JP (3) JP6974681B2 (enExample)
KR (1) KR20180028530A (enExample)
CN (3) CN108026512B (enExample)
AU (2) AU2016300128B2 (enExample)
BR (1) BR112018001660A2 (enExample)
CA (2) CA3156128A1 (enExample)
DK (3) DK3421590T3 (enExample)
ES (5) ES2970269T3 (enExample)
HK (1) HK1252582B (enExample)
MX (2) MX380813B (enExample)
WO (1) WO2017017184A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
JP6974681B2 (ja) * 2015-07-29 2021-12-01 オーエヌケー セラピューティクス リミテッド 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US10799536B2 (en) 2016-12-09 2020-10-13 Onk Therapeutics Limited Method of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38
IL267543B2 (en) * 2017-01-06 2024-07-01 Immunitybio Inc Modified nk-92 cells and compositions thereof for use in the treatment of cancer and methods of preparation thereof
EP3580341A4 (en) * 2017-02-09 2020-11-04 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and compositions and methods thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
DE102017002645A1 (de) * 2017-03-17 2018-09-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Bestrahlung von Säugetierzellen mit Elektronenstrahlen und/oder Röntgenstrahlen
US11903968B2 (en) 2017-07-21 2024-02-20 Cellectis Engineered immune cells resistant to tumor microenvironment
WO2019016360A1 (en) * 2017-07-21 2019-01-24 Cellectis MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
JP2021503954A (ja) * 2017-11-24 2021-02-15 オーエヌケイ セラピューティクス リミテッド 腫瘍細胞を標的とする改変されたナチュラルキラー細胞およびナチュラルキラー細胞株
CN113518826A (zh) * 2018-05-16 2021-10-19 全国儿童医院研究所 利用cas9核糖核蛋白来产生敲除的原代和扩增的人nk细胞
US20210230542A1 (en) * 2018-06-06 2021-07-29 Stemcell Technologies Canada Inc. Kits, compositions and methods for cell enrichment
CN108743595B (zh) * 2018-06-08 2020-11-27 厦门诺康得生物科技有限公司 一种nk细胞免疫检查点抑制剂及其制备方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US12410402B2 (en) 2018-11-21 2025-09-09 Indapta Therapeutics, Inc. Methods for expansion of natural killer (NK) cell subset and related compositions and methods
BR112021010297A2 (pt) 2018-11-28 2021-08-24 Board Of Regents, The University Of Texas System Edição de genomas multiplexadores de células imunes para aumentar a funcionalidade e resistência ao ambiente supressivo
MX2021009742A (es) * 2019-02-15 2021-12-10 Editas Medicine Inc Celulas asesinas naturales (nk) modificadas para inmunoterapia.
CN109908155A (zh) * 2019-03-11 2019-06-21 上海中医药大学 丹参酮ⅱa的药物用途
WO2020189942A1 (ko) * 2019-03-15 2020-09-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
KR102292657B1 (ko) 2019-03-15 2021-08-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
MX2021011373A (es) * 2019-03-21 2022-01-06 Onk Therapeutics Ltd Celulas efectoras inmunitarias modificadas con mayor resistencia a la muerte celular.
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
CN109970869A (zh) * 2019-04-12 2019-07-05 南京卡提医学科技有限公司 一种靶向人trail死亡受体的嵌合受体配体及其应用
RU2731293C1 (ru) 2019-04-12 2020-09-01 Игорь Петрович Белецкий Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний
EP3789485A1 (en) 2019-09-06 2021-03-10 ONK Therapeutics Limited Cellular therapies for cancer
CA3153197A1 (en) 2019-10-03 2021-04-08 Ryan T. Gill Crispr systems with engineered dual guide nucleic acids
CN111849896B (zh) * 2020-07-31 2022-07-01 广东昭泰体内生物医药科技有限公司 一种car-nk细胞培养基及其应用
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CA3209863A1 (en) 2021-02-25 2022-09-01 Andrea BARGHETTI Compositions and methods for targeting, editing, or modifying genes
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
EP4370676A2 (en) 2021-06-18 2024-05-22 Artisan Development Labs, Inc. Compositions and methods for targeting, editing or modifying human genes
EP4355860A1 (en) 2021-06-18 2024-04-24 ONK Therapeutics Limited Double knockout natural killer cells
CN113684180B (zh) * 2021-08-31 2023-05-26 山东大学第二医院 一种提高骨髓瘤杀伤活性的nk细胞制备方法
CN114544971B (zh) * 2022-02-22 2024-08-30 广东省科学院动物研究所 一种功能蛋白活性的检测方法
WO2023167882A1 (en) 2022-03-01 2023-09-07 Artisan Development Labs, Inc. Composition and methods for transgene insertion
CN114796483B (zh) * 2022-06-28 2022-11-08 北京大学 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物
EP4353741A1 (en) 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells
JP2025536042A (ja) 2022-11-10 2025-10-30 オーエヌケイ セラピューティクス リミテッド 免疫調節薬を用いた併用療法
CN116590237B (zh) * 2023-05-29 2023-10-31 上海贝斯昂科生物科技有限公司 一种遗传修饰的自然杀伤细胞及其制备和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1299522B1 (en) 2000-06-30 2011-11-02 University Of Louisville Research Foundation, Inc. Alteration of cell membrane
CA2388441A1 (en) 2002-06-10 2003-12-10 Wei-Ping Min Immunomodulation using rna interference
JP2008505071A (ja) * 2004-07-02 2008-02-21 アヴァリス・アクチエボラーグ 細胞を遺伝学的に活性化する方法、および、該細胞の使用
DK2112162T3 (da) * 2004-07-10 2015-02-23 Fox Chase Cancer Ct Genetisk modificerede humane naturlige dræbercellelinjer
EP1621550A1 (en) * 2004-07-29 2006-02-01 Dompé S.P.A. Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
EP2595637B1 (en) 2010-07-22 2017-11-01 Cellect Biotherapeutics Ltd. Regulatory immune cells with enhanced targeted cell death effect
CN102908612A (zh) * 2011-08-02 2013-02-06 北京诺赛基因组研究中心有限公司 TRAIL截短型变异体活化NF-κB和在炎症反应中的应用
EP3763810A3 (en) * 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
CN103073644B (zh) * 2012-12-31 2014-03-12 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
RU2015140941A (ru) * 2013-02-27 2017-03-30 Те Брод Инститьют, Инк. Экспрессия генов, влияющих на баланс т-клеток, их композиции и способы применения
CN105393019B (zh) 2013-07-25 2017-10-17 株式会社普利司通 隔振装置
NZ717534A (en) * 2013-08-22 2022-04-29 Council Queensland Inst Medical Res Immunoreceptor modulation for treating cancer and viral infections
CA2926698C (en) * 2013-10-15 2021-06-22 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
ES2939760T3 (es) * 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
PL3888674T3 (pl) 2014-04-07 2024-09-23 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
KR102827558B1 (ko) 2014-04-18 2025-07-11 에디타스 메디신, 인코포레이티드 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분
US10577417B2 (en) * 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP4269601A3 (en) * 2015-03-27 2024-01-10 President and Fellows of Harvard College Modified t cells and methods of making and using the same
EP4043556B1 (en) * 2015-06-30 2024-02-07 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
AR105433A1 (es) * 2015-07-21 2017-10-04 Novartis Ag Métodos para mejorar la eficacia y expansión de las células inmunes
JP6974681B2 (ja) 2015-07-29 2021-12-01 オーエヌケー セラピューティクス リミテッド 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
JP2021503954A (ja) * 2017-11-24 2021-02-15 オーエヌケイ セラピューティクス リミテッド 腫瘍細胞を標的とする改変されたナチュラルキラー細胞およびナチュラルキラー細胞株
WO2021209625A1 (en) * 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Also Published As

Publication number Publication date
RU2018104871A (ru) 2019-08-28
ES2876938T3 (es) 2021-11-15
US10034925B2 (en) 2018-07-31
CN116064401A (zh) 2023-05-05
EP3971284A1 (en) 2022-03-23
EP3434762B1 (en) 2021-03-17
US20170157230A1 (en) 2017-06-08
EP3317401A1 (en) 2018-05-09
ES2701338T3 (es) 2019-02-21
DK3317401T3 (da) 2019-01-02
CN116064400B (zh) 2025-09-16
MX2018001074A (es) 2018-11-12
KR20180028530A (ko) 2018-03-16
EP3434762A1 (en) 2019-01-30
US20180326029A1 (en) 2018-11-15
EP3878951A1 (en) 2021-09-15
ES2939084T3 (es) 2023-04-18
WO2017017184A1 (en) 2017-02-02
CA2993796A1 (en) 2017-02-02
MX380813B (es) 2025-03-12
AU2022203339A1 (en) 2022-06-09
MX2020010014A (es) 2020-10-14
HK1252582B (en) 2020-02-07
HK1252582A1 (en) 2019-05-31
JP2018522592A (ja) 2018-08-16
JP7359346B2 (ja) 2023-10-11
CA3156128A1 (en) 2017-02-02
RU2018104871A3 (enExample) 2020-08-17
EP3828266B1 (en) 2022-11-23
US10960064B2 (en) 2021-03-30
ES2890859T3 (es) 2022-01-24
BR112018001660A2 (pt) 2018-09-18
US20210138051A1 (en) 2021-05-13
AU2016300128B2 (en) 2022-03-17
EP3971284B1 (en) 2023-11-08
EP3421590A1 (en) 2019-01-02
AU2016300128A1 (en) 2018-02-22
EP3317401B1 (en) 2018-10-03
EP3421590B1 (en) 2021-07-14
ES2970269T3 (es) 2024-05-27
JP2021169473A (ja) 2021-10-28
CN108026512A (zh) 2018-05-11
JP6974681B2 (ja) 2021-12-01
CN116064400A (zh) 2023-05-05
EP3828266A1 (en) 2021-06-02
JP2021178824A (ja) 2021-11-18
DK3421590T3 (da) 2021-10-04
CA2993796C (en) 2024-02-20
DK3434762T3 (da) 2021-06-07

Similar Documents

Publication Publication Date Title
CN108026512B (zh) 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系
AU2017371514B2 (en) Improved NK-based cell therapy
WO2021044060A1 (en) Cellular therapies for cancer
RU2772348C2 (ru) Модифицированные клетки-естественные киллеры и линии клеток-естественных киллеров с повышенной цитотоксичностью
RU2776890C9 (ru) Клеточная терапия, основанная на улучшенных клетках-естественных киллерах
RU2776890C2 (ru) Клеточная терапия, основанная на улучшенных клетках-естественных киллерах
HK40069678A (en) Modified natural killer cells and natural killer cell lines having increased cytotoxicity
HK40069678B (en) Modified natural killer cells and natural killer cell lines having increased cytotoxicity
HK40043004A (en) Modified natural killer cells and natural killer cell lines having increased cytotoxicity
HK40002288B (en) Modified natural killer cells and natural killer cell lines having increased cytotoxicity
HK40002288A (en) Modified natural killer cells and natural killer cell lines having increased cytotoxicity
HK40001552A (en) Modified natural killer cells and natural killer cell lines having increased cytotoxicity
HK40001552B (en) Modified natural killer cells and natural killer cell lines having increased cytotoxicity
JP2022526504A (ja) 細胞死に対する耐性が増大した改変免疫エフェクター細胞
EP3712257A1 (en) Modified natural killer cells with increased resistance to cell death

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Ai Erlangaowei

Applicant after: UK Medical Ltd.

Address before: Donegal, Ireland

Applicant before: Onkimmune Ltd.

GR01 Patent grant
GR01 Patent grant